Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

S*BIO CEO Jan-Anders Karlsson On Development Success In Singapore: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Founded in 2000 as a joint venture between Chiron and the Economic Development Board of Singapore, S*BIO was one of the first biotech companies in Singapore. The company's pipeline consists of novel targeted small molecule drugs for the treatment of cancer with leading programs around histonedeacetylases and kinases. S*BIO announced Oct. 20 completion of a $26 million Series-B financing led by Bio*One Capital and Aravis Venture, which will allow the company to more forward into Phase II clinical development of its two lead oncology compounds. S*BIO CEO Jan-Anders Karlsson recently sat down with PharmAsia News' Australia bureau to discuss its pipeline and operations out of Singapore.

You may also be interested in...



Singapore’s S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara

The multi-kinase inhibitor might have stalled after S*BIO focused on funding its first two candidates in the clinic, CEO says. The company is still involved in preclinical development.

Singapore S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara

PERTH, Australia - Just two weeks after announcing a development collaboration deal with Onyx Pharmaceuticals on JAK2 inhibitors, Singapore-based S*BIO announced it inked a licensing deal Jan. 21 with San Diego-based Tragara Pharmaceuticals covering its multi-kinase inhibitor SB1317 for leukemia

Singapore S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara

PERTH, Australia - Just two weeks after announcing a development collaboration deal with Onyx Pharmaceuticals on JAK2 inhibitors, Singapore-based S*BIO announced it inked a licensing deal Jan. 21 with San Diego-based Tragara Pharmaceuticals covering its multi-kinase inhibitor SB1317 for leukemia

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel